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urrent Selection
f Optimal Prosthetic
ortic Valve Replacement
n Middle-Aged Patients
till Dealer’s Choice*
eter H. Stone, MD
oston, Massachusetts
election of the type of prosthetic aortic valve replacement
AVR) is frequently a difficult judgment decision affecting
he majority of patients who require surgical AVR. The
hoices generally include bioprosthetic valves (stented or
tentless porcine bioprosthesis, stented pericardial prosthe-
is) and mechanical prosthetic valves (bileaflet or monoleaf-
et) (1,2). Mechanical valves have the advantage of structural
tability but the disadvantage of requiring anticoagulation
ith warfarin, whereas bioprostheses have the advantage of
ot requiring anticoagulation with warfarin but the disad-
antage of being subject to time-related structural valve
ailure (2). Although some patients are clearly better served
ith one valve type or another, as noted below, the choice
See page 1862
or many patients has been at the discretion of the patient or
hysician. A number of landmark studies over the past 30
ears have shed critical light on the outcome of patients who
eceived one design or another (3–8), and guidelines have
een formulated and more recently updated (2). Many of
he patients in the previous long-term follow-up studies that
ere used to create the current guidelines, however, received
heir AVR in the late 1970s and early 1980s, and surgical
echniques, valve design, and concomitant medications have
mproved substantially since that time (2). An update
oncerning clinical outcomes after AVR in the current
herapeutic era with more current valve designs would be of
normous value.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.1
From the Cardiovascular Division, Brigham & Women’s Hospital, Harvard
edical School, Boston, Massachusetts.Some complications associated with AVR are similar
etween bioprosthetic and mechanical prostheses, whereas
thers are more unique to one valve type or another.
ystemic thromboembolism. Systemic thromboembolism
as been consistently similar in patients receiving either a
issue or a mechanical prosthesis (3,4), although the respon-
ible mechanisms might be different in the 2 types of valves:
nadequate anticoagulation in the setting of a mechanical
rosthesis versus structural valve degeneration in the setting
f a bioprosthetic valve.
emorrhage. Hemorrhage is typically related to anticoag-
lation therapy and is generally increased in patients with a
echanical prosthesis, which requires lifelong anticoagula-
ion, compared with patients with a bioprosthesis, in whom
nticoagulation is typically not used or used routinely only
arly post-operatively (2–4). The bleeding events in pa-
ients with a mechanical prosthesis are most often due to
xcessive anticoagulation, which generally can be ade-
uately managed with careful management of the level of
nticoagulation (1,2).
tructural valve degeneration. Structural valve degenera-
ion primarily affects leaflets of bioprosthetic valves, al-
hough mechanical failure of mechanical prostheses oc-
urred with older generations of mechanical valves (1).
ewer generations of bioprosthetic and pericardial valves
ave been reported to have less structural degeneration than
arlier generations of bioprosthetic valves (1,2,9–11), but
ther studies suggest that there is no difference (2). Host-
elated factors are critically important to determine the
ikelihood of structural valve degeneration, and age is
robably the most important factor. The rate of biopros-
hetic valve failure is10% at 10 years in patients65 years
f age but is 20% to 30% in patients 40 years of age
1,2,10,12). Other important predictors of structural valve
egeneration include systemic hypertension, renal insuffi-
iency, left ventricular hypertrophy, poor left ventricular
unction, and prosthetic valve size (1,9,10).
The most recently updated guidelines indicate that the
xisting information does not necessarily obligate one type
f valve over another in most patients (Class IIa, Level of
vidence: C) and emphasize that patient and physician
reference is an important determinant of prosthesis selec-
ion (2). Age also importantly influences the recommen-
ation: in patients 65 years of age in whom there is no
ontraindication for warfarin therapy a mechanical pros-
hesis is generally recommended, whereas in older pa-
ients 65 years of age a bioprosthetic valve is generally
ecommended (1,2).
The most definitive way to address the comparative value
f tissue versus mechanical valve prostheses is a randomized
linical trial, but the only 2 previous randomized trials (the
dinburgh Heart Valve Trial [4] and the Veterans Affairs
ooperative Study on Valvular Heart Disease [3]) enrolled
atients in a very different era of surgical technique (1975 to
982) and compared prosthetic valves that are no longer
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Optimal Selection of Prosthetic Valve Type for AVR November 10, 2009:1869–71mplanted (Bjork-Shiley tilting-disc valve or first-generation
orcine heterografts). In this issue of the Journal, Stassano et
l. (13) present the results of a new landmark, prospective,
andomized trial of prosthetic aortic valves in patients who
ere enrolled from 1995 to 2003. These investigators
ocused their trial on patients with aortic valve disease
etween 55 and 70 years of age because, as noted in the
receding text, patients younger than 55 years of age are
enerally recommended to have a mechanical valve prosthe-
is and patients older than 70 years of age are generally
ecommended to have a bioprosthetic valve. Patients in this
middle-age” group could potentially be well served with
ither type of valve, and the investigators enrolled only those
atients who left the decision concerning which valve type
o be implanted to the discretion of the surgeon. Of 392
atients (35% of all patients with aortic valve disease) in this
ge group, 310 were randomized to receive either a biopros-
heses (Carpentier-Edwards SAV or Pericardial valve, Ir-
ine, California) or a mechanical bileaflet valve (St. Jude
edical, Seattle, Washington, or CarboMedics, Austin,
exas), valve choices that remain in widespread use today.
oronary artery bypass graft was concomitantly performed
n approximately 25% of patients in each group. Patients
ith a mechanical AVR received lifelong warfarin, and
atients with a bioprosthesis received warfarin for only 8 to
2 weeks. Medication management was left to the discre-
ion of the local treating physician. Perioperative mortality
as low and similar in both mechanical and bioprosthetic
roups (2.6% vs. 3.9%, respectively, p  0.4). At late
ollow-up (mean 106  28 months) the outcomes were also
imilar in both groups: overall mortality (27.5% vs. 30.6%),
ardiac-related mortality (16.7% vs. 21.7%), valve-related
ortality (6.7% vs. 8.1%), and major adverse prosthesis-
elated events (23.4% vs. 28.6%). Independent predictors of
ate mortality were related to host characteristics (New York
eart Association functional class, low ejection fraction, or
oncomitant coronary artery bypass graft performed) and
ot to valve type implanted. There were no differences in
orbidity (thromboembolism, bleeding, endocarditis, valve
hrombosis, and nonstructural dysfunction) between the 2
andomized groups, although—as expected—the biopros-
hetic valve group exhibited more frequent structural valve
ysfunction (2.17%/patient-year vs. 0%/patient-year, p 
.0001) and more frequently required reoperation (2.32%/
atient-year vs. 0.62%/patient-year, p  0.0003) compared
ith the mechanical prosthesis group. The occurrence of
ajor adverse prosthetic-related events began to show an
mportant divergence beginning at 10 years, when structural
alve degeneration and reoperation became more frequent
n the patients who received a bioprosthetic AVR.
The results of this important study reinforce and expand
number of major observations from the prior era. Al-
hough perioperative mortality has improved since the late
970s and early 1980s, the long-term outcomes comparing
he 2 types of valves are generally as similar now with more
odern generations of the respective valve types as theyere with earlier generations of the valves 30 years ago. An
nteresting issue from the Stassano et al. (13) study is that
he difference in bleeding between the 2 groups was only a
tatistical trend (p  0.08), in contrast to previous trials in
hich bleeding was significantly more common in the
echanical prosthesis group in whom lifetime warfarin
herapy is required (3,4). As the authors suggest, the
xplanation might be that 21% of patients in the biopros-
hetic group received long-term warfarin therapy and 26%
eceived antiplatelet therapy. They note that the use of
arfarin was dictated by the local treating physician and was
ikely initiated for a variety of indications necessitating
nticoagulation that middle-aged patients with aortic valve
isease acquire regardless of prosthetic valve type implanted.
leeding primarily occurred in those patients who were
aking warfarin, regardless of valve type implanted.
It should also be emphasized that these patients were only
ollowed for a mean of 106 months. In the randomized
eterans Administration trial (3), the significantly increased
ortality associated with implantation of a bioprosthetic
alve only became evident after 10 years of follow-up when
ncreased mortality associated with reoperation for struc-
ural valve degeneration occurred. The very long-term
utcomes will be very important to follow in the Stassano
rial to further guide valve selection, because most of the
iddle-aged patients enrolled can be expected to survive
ell beyond 10 years post-operatively.
How are the results from this new randomized trial to be
ncorporated into our management decisions with patients
ith aortic valve disease who require AVR? I think very
ittle has changed. The authors have provided an invaluable
pdate with a randomized clinical trial format and current
enerations of mechanical and bioprosthetic valves. As the
urrent guidelines recommend (2), even before an awareness
f the Stassano et al. (13) trial, patient and physician
reference concerning valve selection remains paramount.
here are no major differences in terms of mortality
etween the 2 valve types, but patients receiving a biopros-
hetic valve can be assured of developing structural valve
eterioration after approximately 10 years and will require
eoperation, whereas those patients taking warfarin (primar-
ly the patients receiving a mechanical valve) will likely
evelop more bleeding. Patients and physicians can now
ecide on valve choice based on experience in the current
herapeutic era and the current generations of the respective
alve types.
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